The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1363
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Duloxetine (Cymbalta) for Chronic Musculoskeletal Pain

Previously approved by the FDA for treatment of depression, general anxiety disorder, diabetic peripheral neuropathic pain and fibromyalgia,1,2 duloxetine (Cymbalta – Lilly) has now also been approved for treatment of chronic musculoskeletal pain.

MECHANISM OF ACTION — Duloxetine is a selective serotonin and norepinephrine reuptake inhibitor (SNRI). Its mechanism of action in reducing pain is unknown.

CLINICAL STUDIES — Chronic Low Back Pain – Three double-blind, randomized, 3-month trials of duloxetine in a total of >1000 patients with chronic (≥6 months) low back pain have been published and are summarized in the package insert.3-5 All were conducted by employees of the manufacturer. Two of the three trials found duloxetine more effective than placebo in reducing pain, as measured by Brief Pain ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1363
 Downloadable, electronic issue - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian